merck germany products

Merck, SpringWorks

Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics

Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks Therapeutics Inc (NASDAQ:SWTX), which has a market capitalization of $4.02 billion,

Hosted on MSN · 1d

Germany's Merck in advanced talks to acquire US biotech firm SpringWorks

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") By Sabrina Valle and Patricia Weiss NEW YORK/FRANKFURT (Reuters) -Merck KGaA,

Hartford Business · 2d

CT drugmaker in ‘advanced talks’ to be acquired by Germany’s Merck

Stamford-based SpringWorks Therapeutics, a commercial-stage biotech company developing treatments for rare diseases and cancer, is in “advanced talks” to be acquired by Germany’s Merck, according to Reuters.

The Wall Street Journal on MSN · 1d

Germany’s Merck in Talks to Buy SpringWorks Therapeutics

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical company that specializes in rare diseases and cancer.

Investing.com on MSN · 1d

Merck KGaA in advanced talks to acquire SpringWorks Therapeutics

KGaA said it is in advanced discussions regarding a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical firm specializing in rare diseases and cancer treatments.

pharmaphorum1d

Merck confirms its interest in buying SpringWorks

Merck said in a brief statement that discussions are "advanced" but noted that "critical conditions have yet to be met" ...

FiercePharma1d

UPDATE: Merck KGaA sets its sights on acquisition of Ogsiveo maker SpringWorks

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

2don MSN

SpringWorks Stock Jumps More Than 30% on News of Possible Deal

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.

13d

Merck to stop lung condition drug study early due to strong efficacy data

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results